Want to see DOCS full AI Analyst Report?
DOCS Stock Chart & Stats
$20.42
-$0.03(-0.15%)
At close: 4:00 PM EDT
$20.42
-$0.03(-0.15%)
Day’s Range― - ―
52-Week Range$17.15 - $76.51
Previous Close$20.42
Volume2.18M
Average Volume (3M)3.11M
Market Cap
$4.74B
Enterprise Value$3.29K
Total Cash (Recent Filing)$687.79M
Total Debt (Recent Filing)$9.67M
Price to Earnings (P/E)27.9
Beta1.70
Next Earnings
Nov 05, 2026EPS Estimate
0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.89
Shares Outstanding127,349,365
10 Day Avg. Volume2,613,670
30 Day Avg. Volume3,107,366
Financial Highlights & Ratios
PEG Ratio-1.89
Price to Book (P/B)4.58
Price to Sales (P/S)6.76
P/FCF Ratio13.72
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$31.14Price Target Upside52.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)1.36
Revenue Forecast (FY)$675.98M
Bulls Say, Bears Say
Bulls Say
High Profitability And Scalable MarginsSustained very high gross and operating margins signal a scalable, software-like business model with strong unit economics. These margins provide durable cash generation to fund AI investments, buybacks, and R&D while insulating earnings from normal cyclical revenue swings.
Very Strong Balance Sheet And Low LeverageMinimal debt and a large equity base give the company high financial flexibility to invest in product development, absorb AI investment timing volatility, and execute sizable share repurchases without stressing liquidity or requiring external financing.
Validated Enterprise AI Traction And Safety ControlsIndependent validation and embedded safety controls (expert-verified drug reference, physician PeerCheck editors) create an enterprise moat for clinical AI. This credibility accelerates hospital procurement and long-term contract wins, supporting durable monetization of AI products.
Bears Say
Decelerating Revenue GrowthRevenue expansion has slowed versus prior years and management expects only modest Q2 growth, relying on AI search to reaccelerate in Q3. Prolonged deceleration would compress long-term upside and force heavier reliance on margin expansion or buybacks to sustain returns.
Gross Margin Pressure From AI ComputeManagement recognizes ~90% of incremental AI costs hit cost of revenue, pulling gross margins down into the mid-to-high 80s. If compute intensity or pricing pressure persists, structural margin compression could reduce free cash flow and limit reinvestment capacity.
Customer Concentration And Pharma Budget SensitivityA high share of revenue from a limited cohort of large customers creates concentration risk and ties growth to enterprise/pharma budgets. Tight or delayed innovation budgets at a few buyers could materially affect top-line stability despite strong retention metrics.
Doximity News
DOCS FAQ
What was Doximity, Inc.’s price range in the past 12 months?
Doximity, Inc. lowest stock price was $17.15 and its highest was $76.51 in the past 12 months.
What is Doximity, Inc.’s market cap?
Doximity, Inc.’s market cap is $4.74B.
When is Doximity, Inc.’s upcoming earnings report date?
Doximity, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 82 days.
How were Doximity, Inc.’s earnings last quarter?
Doximity, Inc. released its earnings results on Aug 06, 2026. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.303 by -$0.013.
Is Doximity, Inc. overvalued?
According to Wall Street analysts Doximity, Inc.’s price is currently Undervalued.
Does Doximity, Inc. pay dividends?
Doximity, Inc. does not currently pay dividends.
What is Doximity, Inc.’s EPS estimate?
Doximity, Inc.’s EPS estimate is 0.34.
How many shares outstanding does Doximity, Inc. have?
Doximity, Inc. has 127,349,365 shares outstanding.
What happened to Doximity, Inc.’s price movement after its last earnings report?
Doximity, Inc. reported an EPS of $0.29 in its last earnings report, missing expectations of $0.303. Following the earnings report the stock price went up 32.623%.
Which hedge fund is a major shareholder of Doximity, Inc.?
Currently, no hedge funds are holding shares in DOCS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Doximity Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$31.14 (52.51% Upside)
$31.14 (52.51% Upside)
Blogger Sentiment
Neutral
DOCS Sentiment 59%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 112.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 2.2%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.33%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.01%
Trailing 12-Months
Company Description
Doximity, Inc.
Doximity, Inc. provides a digital platform, hosted in the cloud, specifically designed for healthcare practitioners throughout the United States. This platform delivers a suite of specialized tools, empowering its members to connect with peers, streamline patient treatment, conduct remote consultations, access current medical information and research, and advance their professional careers. Its primary clientele consists of pharmaceutical companies and healthcare organizations. Established in 2010, the entity initially operated as 3MD Communications, Inc. before rebranding to Doximity, Inc. in June of that year. The company's corporate headquarters are situated in San Francisco, California.
DOCS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call combined strong financial and operational positives — revenue and adjusted EBITDA beats, raised full‑year guidance, robust cash balance, aggressive share repurchases, independent validation of Doximity Ask, rapid clinician adoption and meaningful enterprise wins — with managed near‑term tradeoffs driven by deliberate AI investment. Short‑term impacts include lower gross margin from compute spend, higher OpEx and a cautious Q2 growth comp, but management positioned these as intentional investments to capture a large long‑term AI opportunity while preserving high margins. Overall the positives (beat, guidance raise, product validation, adoption and balance sheet strength) outweigh the near‑term headwinds tied to investment cadence and timing of AI monetization.View all DOCS earnings summariesDOCS Revenue Breakdown
93.00% Subscription
7.00% Other
DOCS Stock 12 Month Forecast
Average Price Target
$31.14
▲(52.51% Upside)
Technical Analysis
Ownership Overview
3.09% Insiders
26.74% Mutual Funds
12.57% Other Institutional Investors
34.09% Public Companies and Individual Investors